

Initial Review of Candidate Agents

Therapeutic agents that **can be placed in a Phase II or Phase III Master Protocol** for investigation



Compounds that are **to be re-evaluated** upon receipt of additional data



FOLLOW UP

Compounds that may **require longer term preclinical and clinical development**



DEFER

Compounds that **should not be considered for future rounds** of prioritization

